Litcius/Paper detail

Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Fengcai Zhu, Chunlan Zhuang, Kai Chu, Liang Zhang, Hui Zhao, Shoujie Huang, Yingying Su, Hong‐Yan Lin, Changlin Yang, Han-Min Jiang, Xia Zang, Donglin Liu, Hongxing Pan, Yuemei Hu, Xiaohui Liu, Qi Chen, Qiaoqiao Song, Jiali Quan, Zehong Huang, Guohua Zhong, Junyu Chen, Jinle Han, Hong Sun, Lunbiao Cui, Jingxin Li, Yixin Chen, Tianying Zhang, Xiangzhong Ye, Changgui Li, Ting Wu, Jun Zhang, Ningshao Xia

2022The Lancet Respiratory Medicine139 citationsDOIOpen Access PDF

Topics & Concepts

MedicineImmunogenicityPlaceboAdverse effectELISPOTVaccinationInfluenza vaccineNasal administrationInternal medicineClinical trialRandomized controlled trialImmunologyVirologyAntibodyImmune systemT cellPathologyAlternative medicineSARS-CoV-2 and COVID-19 ResearchAdvanced Drug Delivery SystemsRespiratory viral infections research